Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide

The alpha-1 antitrypsin (AAT) haplotype Pi*S, when inherited along with the Pi*Z haplotype to form a Pi*SZ genotype, can be associated with pulmonary emphysema in regular smokers, and less frequently with liver disease, panniculitis, and systemic vasculitis in a small percentage of people, but this connection is less well established. Since the detection of cases can allow the application of preventive measures in patients and relatives with this congenital disorder, the objective of this study was to update the prevalence of the SZ genotype to achieve accurate estimates of the number of Pi*SZ subjects worldwide, based on studies performed according to the following criteria: 1) samples representative of the general population, 2) AAT phenotyping characterized by adequate methods, and 3) selection of studies with reliable results assessed with a coefficient of variation calculated from the sample size and 95% confidence intervals. Studies fulfilling these criteria were used to develop tables and maps with an inverse distance-weighted (IDW) interpolation method, to provide numerical and geographical information of the Pi*SZ distribution worldwide. A total of 262 cohorts from 71 countries were included in the analysis. With the data provided by these cohorts, a total of 1,490,816 Pi*SZ were estimated: 708,792 in Europe; 582,984 in America and Caribbean; 85,925 in Africa; 77,940 in Asia; and 35,176 in Australia and New Zealand. Remarkably, the IDW interpolation maps predicted the Pi*SZ prevalence throughout the entire world even in areas lacking real data. These results may be useful to plan strategies for future research, diagnosis, and management of affected individuals.

[1]  M. Miravitlles,et al.  Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update , 2017, International journal of chronic obstructive pulmonary disease.

[2]  C. Mueller,et al.  Alpha-1 Antitrypsin Deficiency , 2017, Methods in Molecular Biology.

[3]  D. Lomas,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[4]  J. Katzmann,et al.  Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles , 2015, Respiratory Research.

[5]  E. Piitulainen,et al.  The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34. , 2015, Annals of the American Thoracic Society.

[6]  M. Miravitlles,et al.  Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals , 2015, COPD.

[7]  I. Blanco,et al.  Role of alpha‐1 antitrypsin in human health and disease , 2014, Journal of internal medicine.

[8]  J. Teckman.  Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy , 2013, COPD.

[9]  M. Miravitlles,et al.  Clinical phenotypes of Italian and Spanish patients with &agr;1-antitrypsin deficiency , 2012, European Respiratory Journal.

[10]  F. D. de Serres,et al.  Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method , 2012, Hepatitis monthly.

[11]  F. D. de Serres,et al.  Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review , 2012, Therapeutic advances in respiratory disease.

[12]  F. D. de Serres,et al.  Ethnic differences in alpha-1 antitrypsin deficiency in the United States of America , 2010, Therapeutic advances in respiratory disease.

[13]  R. Stockley,et al.  CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. , 2009, Chest.

[14]  David W. S. Wong,et al.  An adaptive inverse-distance weighting spatial interpolation technique , 2008, Comput. Geosci..

[15]  A. Krūmiņa,et al.  Age of SERPINA1 Gene PI Z Mutation: Swedish and Latvian Population Analysis , 2008, Annals of human genetics.

[16]  F. D. de Serres,et al.  Estimated numbers and prevalence of PI*S and PI*Z deficiency alleles of α1-antitrypsin deficiency in Asia , 2006, European Respiratory Journal.

[17]  F. D. de Serres,et al.  Estimated numbers and prevalence of PI*S and PI*Z alleles of α1-antitrypsin deficiency in European countries , 2006, European Respiratory Journal.

[18]  K. Ohlsson,et al.  Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. , 2005, Chest.

[19]  E. Silverman,et al.  The protease inhibitor PI*S allele and COPD: a meta-analysis , 2005, European Respiratory Journal.

[20]  N. Seersholm,et al.  α1-Antitrypsin deficiency · 1: Epidemiology of α1-antitrypsin deficiency , 2004, Thorax.

[21]  A. Dirksen,et al.  Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency: Executive summary , 2003 .

[22]  D. Lomas,et al.  Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. , 2002, The Journal of clinical investigation.

[23]  M. Miravitlles.  Alpha1-anti-trypsin deficiency: epidemiology and incidence. , 2002, Respiratory medicine.

[24]  F. D. de Serres,et al.  Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. , 2002, Chest.

[25]  I. Blanco,et al.  Distribution of α1‐antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta‐analysis , 2001, Clinical genetics.

[26]  I. Blanco,et al.  Alpha‐1‐antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys , 2001, Clinical genetics.

[27]  D. Hutchison.  Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. , 1998, Respiratory medicine.

[28]  M. Schluchter,et al.  Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. , 1996, American journal of respiratory and critical care medicine.

[29]  D. Lomas,et al.  The mechanism of Z alpha 1-antitrypsin accumulation in the liver. , 1992, Nature.

[30]  R. Crystal,et al.  Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. , 1991, Chest.

[31]  R. Crystal,et al.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. , 1988, The American review of respiratory disease.

[32]  R. Crystal,et al.  Molecular basis of alpha-1-antitrypsin deficiency. , 1988, The American journal of medicine.

[33]  R. Crystal,et al.  Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase. , 1988, The American review of respiratory disease.

[34]  K. Kurachi,et al.  Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. , 1984, Biochemistry.

[35]  M. Tobin,et al.  Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. , 1983, British journal of diseases of the chest.

[36]  A. Johnson,et al.  Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978. , 1980, Human genetics.

[37]  D. Cox,et al.  Catabolic rate of alpha1-antitrypsin of of Pi types S, and MMalton and of asialylated M-protein in man. , 1978, Clinical science and molecular medicine.

[38]  T Sveger,et al.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. , 1976, The New England journal of medicine.

[39]  C. Larsson,et al.  Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of alpha1-antitrypsin. , 1976, Scandinavian journal of respiratory diseases.